Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
LPA1 inhibitor claimed to achieve ~ 90% receptor occupancy at ~1 mg QD with a 108-subject, 26-week Phase 2 IPF trial now enrolling, and PIPE-307 , a brain-penetrant M1 inhibitor partnered with J&J Management positions PIPE-791 as differentiated versus Bristol Myers Squibb's zimilparant on target coverage, once-daily dosing and an apparent lack of a hypotension signal so far, while noting BMS's Phase 3 IPF readout in Q4 will be an important external validation. PIPE-307 is in a J&J-run Phase 2 MDD study (124 patients, MADRS at day five); the 2023 collaboration delivered $50M upfront plus $25M equity and $1B in milestones with royalties in the low-to-high teens, and Contineum says it is funded through the middle of while prioritizing PIPE-791. Interested in Contineum Therapeutics, Inc.? Here are five stocks we like better. Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company's clinical priorities and upcoming catalysts during a presentation at the Leerink G
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb (BMY) had its price target raised by HSBC Holdings plc from $53.00 to $60.00. They now have a "hold" rating on the stock.MarketBeat
- Colgate-Palmolive Announces Quarterly Dividend Increase and Elects Christopher Boerner, Ph.D. to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Dave Schuette Joins DataJoint Board of Directors [Yahoo! Finance]Yahoo! Finance
- Defense Lifts Moat Stocks As Tech Stumbles [Seeking Alpha]Seeking Alpha
- ???????(JAK)?????????????(2026?~2036?) [CNET News]CNET News
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- 3/12/26 - Form 4
- BMY's page on the SEC website